Business Context and Reporting Period
This Form 8-K Current Report was filed by Aquestive Therapeutics, Inc. on February 28, 2022. The report addresses a specific corporate event under Item 8.01 (Other Events) rather than providing periodic financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused on clinical trial updates and does not contain financial statements or performance metrics.
Material Changes
The material event reported is the presentation of topline data from a Phase 1 pharmacokinetic study of AQST-109 (epinephrine oral film). On February 28, 2022, John Oppenheimer, M.D., presented a late-breaking poster at the American Academy of Allergy, Asthma, and Immunology (AAAAI) annual meeting in Phoenix, Arizona. The study evaluated the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of the drug in healthy male volunteers.
Guidance, Outlook, and Risks
- Management Commentary: The press release referenced in the filing includes "safe harbor" language pursuant to the Private Securities Litigation Reform Act of 1995, indicating that certain statements are forward-looking rather than historical.
- Exhibits: The full text of the press release and the AAAAI Poster Presentation are filed as Exhibits 99.1 and 99.2, respectively.
- Website Disclaimer: The Company reserves the right to discontinue the availability of the Poster Presentation on its website at any time.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific topline data points regarding safety and tolerability.
- Examine Exhibit 99.2 (Poster Presentation) for detailed pharmacokinetic and pharmacodynamic results.
- Verify the status of the AQST-109 development program relative to the Phase 1 study outcomes.
- Check for any subsequent filings that may provide updated financial context or clinical trial progress.